In July 2005, Aderis Pharmaceuticals, Inc. was acquired by Schwarz Pharma Ltd. Formerly known as Discovery Therapeutics, Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of receptor subtype-selective compounds for the treatment of cardio-renal diseases. The firm's product pipeline inluded adenosine agonists and antagonists for the diagnosis and treatment of cardiovascular disease and FLAP antagonists for the treatment of chronic kidney disease. Primarily focused on CNS, cardiovascular and renal therapeutics, the firmorganized around developing small molecule drug candidates that act selectively to either inhibit or increase the activity of certain proteins, such as receptors and enzymes that regulate important physiologic functions. That the selectivity of drug candidates offered the potential for safe and effective therapies with minimal side effects with small molecule drug candidates offering dosing flexibility for optimal patient convenience.
